Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System (MRI-PEM)
Primary Purpose
Breast Cancer
Status
Terminated
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
MRI + PEM image
Sponsored by

About this trial
This is an interventional diagnostic trial for Breast Cancer
Eligibility Criteria
Inclusion Criteria:
- Female over 21 years of age;
- with a suspicious lesion found in the breast and recommended for biopsy or have a confirmed diagnosis of cancer;
- and in good health (other than having breast lesions);
- and can lie still in a prone position for 30 minutes in an MRI scanner.
Exclusion Criteria:
- Pregnancy;
- unwilling to give informed consent;
- have implanted prosthetic heart valve,
- pacemaker,
- neurostimulator,
- surgical clips or other metallic implants;
- have engaged in occupations or received orthodontic work which may have caused lodging of ferromagnetic materials in the body;
- are claustrophobic;
- have been allergic to contrast agents;
- are diabetic;
- or have a history of kidney disease.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Diagnostic accuracy with MRI alone
Diagnostic accuracy with MRI + PEM image
Arm Description
The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
The combined PEM/MRI image will be examined.
Outcomes
Primary Outcome Measures
Diagnostic accuracy of combination MRI/positron emission mammography (diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments)
Patients with benign disease on biopsy may be followed for up to 2 years after imaging
Secondary Outcome Measures
Full Information
NCT ID
NCT02426489
First Posted
April 9, 2015
Last Updated
October 5, 2021
Sponsor
Weinberg Medical Physics LLC
Collaborators
University of California, Irvine
1. Study Identification
Unique Protocol Identification Number
NCT02426489
Brief Title
Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System
Acronym
MRI-PEM
Official Title
Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System
Study Type
Interventional
2. Study Status
Record Verification Date
October 2021
Overall Recruitment Status
Terminated
Why Stopped
Subcontract PI left institution.
Study Start Date
July 1, 2015 (Actual)
Primary Completion Date
May 8, 2016 (Actual)
Study Completion Date
May 8, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weinberg Medical Physics LLC
Collaborators
University of California, Irvine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to assess whether the addition of positron emission mammography will add diagnostic value to magnetic resonance imaging of the breast, in patients with lesions of the breast that are suspicious enough to warrant biopsy, or which have been confirmed as containing cancer cells.
Detailed Description
70 eligible subjects will be asked to undergo contrast-enhanced MRI studies of the breast containing the lesion. Subjects will be asked to fast for 6 hours prior to the imaging session. Each subject will be tested for glucose, and if the glucose is not too high, the subject will be injected with a dose of radioactive sugar (fluoro-deoxyglucose) which has been shown in other studies to accumulate in breast cancers. The subject will be asked to sit quietly for 30 minutes and to empty the bladder. The subject will then be asked to be re-examined in the MRI scanner with MRI contrast injection. The examination bed will be moved out of the MRI scanner and detectors of the radioactive sugar will be placed near the breast in order to obtain a positron emission mammogram for a 10-minute period. The subject will then leave the MRI suite.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
1 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diagnostic accuracy with MRI alone
Arm Type
No Intervention
Arm Description
The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
Arm Title
Diagnostic accuracy with MRI + PEM image
Arm Type
Experimental
Arm Description
The combined PEM/MRI image will be examined.
Intervention Type
Device
Intervention Name(s)
MRI + PEM image
Other Intervention Name(s)
flurodeoxyglucose
Intervention Description
Effect of positron emission mammography on diagnostic accuracy
Primary Outcome Measure Information:
Title
Diagnostic accuracy of combination MRI/positron emission mammography (diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments)
Description
Patients with benign disease on biopsy may be followed for up to 2 years after imaging
Time Frame
up to 2 years
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female over 21 years of age;
with a suspicious lesion found in the breast and recommended for biopsy or have a confirmed diagnosis of cancer;
and in good health (other than having breast lesions);
and can lie still in a prone position for 30 minutes in an MRI scanner.
Exclusion Criteria:
Pregnancy;
unwilling to give informed consent;
have implanted prosthetic heart valve,
pacemaker,
neurostimulator,
surgical clips or other metallic implants;
have engaged in occupations or received orthodontic work which may have caused lodging of ferromagnetic materials in the body;
are claustrophobic;
have been allergic to contrast agents;
are diabetic;
or have a history of kidney disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Irving Weinberg, MD PhD
Organizational Affiliation
Weinberg Medical Physics LLC
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System
We'll reach out to this number within 24 hrs